Non-viral vector as vaccine carrier - PubMed (original) (raw)
Review
Non-viral vector as vaccine carrier
Weihsu Claire Chen et al. Adv Genet. 2005.
Abstract
Over the last several years, advances in gene-based delivery technology arising from the field of gene therapy have helped revitalize the field of vaccine development. Genetic vaccination encoding antigen from bacteria, virus, and cancer has shown promise in protective humoral and cellular immunity; however, the potential disadvantages of naked DNA vaccine have reduced the value of the approach. To optimize antigen delivery efficiency as well as vaccine efficacy, the non-viral vector as vaccine carrier, for example, the cationic liposome, has shown particular benefits to circumvent the obstacles that both peptide/protein- and gene-based vaccines have encountered. Liposome-mediated vaccine delivery provides greater efficacy and safer vaccine formulation for the development of vaccine for human use. The success of the liposome-based vaccine has been demonstrated in clinical trials and further human trials are also in progress.
Similar articles
- [Novel vaccines against M. tuberculosis].
Okada M. Okada M. Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese. - Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration.
Hattori Y, Kawakami S, Lu Y, Nakamura K, Yamashita F, Hashida M. Hattori Y, et al. J Gene Med. 2006 Jul;8(7):824-34. doi: 10.1002/jgm.910. J Gene Med. 2006. PMID: 16625665 - DNA vaccines: a role for liposomes.
Gregoriadis G. Gregoriadis G. Curr Opin Mol Ther. 1999 Feb;1(1):39-42. Curr Opin Mol Ther. 1999. PMID: 11249682 Review. - Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force.
Tyagi RK, Garg NK, Sahu T. Tyagi RK, et al. J Control Release. 2012 Aug 20;162(1):242-54. doi: 10.1016/j.jconrel.2012.04.037. Epub 2012 Apr 28. J Control Release. 2012. PMID: 22564369 Review.
Cited by
- Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".
Schoenly KA, Weiner DB. Schoenly KA, et al. J Virol. 2008 Apr;82(7):3166-80. doi: 10.1128/JVI.01634-07. Epub 2007 Nov 7. J Virol. 2008. PMID: 17989174 Free PMC article. Review. No abstract available. - Nano toolbox in immune modulation and nanovaccines.
Azharuddin M, Zhu GH, Sengupta A, Hinkula J, Slater NKH, Patra HK. Azharuddin M, et al. Trends Biotechnol. 2022 Oct;40(10):1195-1212. doi: 10.1016/j.tibtech.2022.03.011. Epub 2022 Apr 19. Trends Biotechnol. 2022. PMID: 35450779 Free PMC article. Review. - A simple but effective cancer vaccine consisting of an antigen and a cationic lipid.
Chen W, Yan W, Huang L. Chen W, et al. Cancer Immunol Immunother. 2008 Apr;57(4):517-30. doi: 10.1007/s00262-007-0390-4. Epub 2007 Aug 28. Cancer Immunol Immunother. 2008. PMID: 17724588 Free PMC article. - Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy.
Wallen M, Aqil F, Spencer W, Gupta RC. Wallen M, et al. Pharmaceutics. 2023 Jun 27;15(7):1832. doi: 10.3390/pharmaceutics15071832. Pharmaceutics. 2023. PMID: 37514019 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources